Choosing a second biologic agent for inflammatory bowel disease patients-cost considerations and clinical outcomes

Research output: Contribution to journal › Editorial › peer-review

All Science Journal Classification (ASJC) codes

@article{f4e96267f1774e849ac5e0d448c0c355,

title = "Choosing a second biologic agent for inflammatory bowel disease patients-cost considerations and clinical outcomes",

author = "Kofi Clarke",

year = "2020",

month = apr,

day = "1",

doi = "10.1093/crocol/otaa032",

language = "English (US)",

volume = "2",

journal = "Crohn's and Colitis 360",

issn = "2631-827X",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Choosing a second biologic agent for inflammatory bowel disease patients-cost considerations and clinical outcomes

AU - Clarke, Kofi

PY - 2020/4/1

Y1 - 2020/4/1

UR - http://www.scopus.com/inward/record.url?scp=85103802446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85103802446&partnerID=8YFLogxK

U2 - 10.1093/crocol/otaa032

DO - 10.1093/crocol/otaa032

M3 - Editorial

AN - SCOPUS:85103802446

SN - 2631-827X

VL - 2

JO - Crohn's and Colitis 360

JF - Crohn's and Colitis 360

IS - 2

ER -